The article reports that pharmaceutical company Roche's bitopertin, a glycine transporter 1 (GlyT1) inhibitor, has failed to improve the negative symptoms of schizophrenia based on two pivotal trials which raises question regarding the therapeutic potential of drug in glycinergic neuromodulation. Topics discussed include prognosis, placebo, and antipsychotic drugs. .